蔚蓝生物 (603739)
Qingdao Vland Biotech Co., Ltd.
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 25302.89
- Circulating A-Shares(W): 25302.89
- Earnings Per Share(RMB): 0.2400
- Net Assets Per Share(RMB): 7.0112
- Operating Revenue(W RMB): 101579.30
- Total Profit(W RMB): 10838.38
- **Net Profit Attributable to Parent(W RMB) **: 6177.92
- Net Profit Growth Rate(%): 51.24
- Weighted Return on Equity(%): 3.5500
- Operating Cash Flow Per Share(RMB): 0.1330
- Undistributed Profit Per Share(RMB): 3.0719
- Capital Reserve Per Share(RMB): 2.7779
2. Main Business
The main business covers:
- Research, development, production, and sales of enzyme preparations
- Research, development, production, and sales of microecological preparations
- Research, development, production, and sales of animal healthcare products
3. Company Basic Information
- Company Name: Qingdao Vland Biotech Group Co., Ltd.
- Listing Date: 2019-01-16
- Industry: Agriculture, Forestry, Animal Husbandry & Fishery - Animal Healthcare
- Address: Room 108, Enterprise Service Center, No. 1318 Wangsha Road, Chengyang District, Qingdao City, Shandong Province
- Website: https://www.vlandgroup.com
- Company Profile: The company's predecessor was Qingdao Pukang Pharmaceutical Co., Ltd., established on February 23, 2005, and renamed to Kunden Pharmaceutical on November 21, 2007. Pursuant to a resolution of the shareholders' meeting, the company, based on the audit report (2011) Hui Suo Shen Zi No. 4-027 issued by Shandong Huide on March 28, 2011, used the audited net asset value of RMB 89,773,599.13 (on a parent company basis) as of December 31, 2010 as the basis, converting it proportionally into 58 million shares to initiate the establishment of a joint stock company through an overall change. The portion of the audited net asset value exceeding the total share capital was recorded into the capital reserve of the joint stock company. Before and after the overall change, all shareholders and their shareholding ratios remained unchanged, and all assets, liabilities, business, and personnel of the limited company were assumed by the newly transformed joint stock company. On May 13, 2011, Shandong Huide issued the capital verification report (2011) Hui Suo Yan Zi No. 4-011 confirming the capital verification for this overall change. On June 20, 2011, Kunden Pharmaceutical obtained the Business License with registration number 370220228001091 issued by the Qingdao Administration for Industry and Commerce.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Qingdao Kunden Industrial Co., Ltd. | Corporate Entity | 11240.74 | 44.42 |
| 2 | Tibet Shancheng Investment Consulting Co., Ltd. | Corporate Entity | 1777.55 | 7.03 |
| 3 | Tibet Sizhuang Investment Consulting Co., Ltd. | Corporate Entity | 1777.55 | 7.03 |
| 4 | Beijing Zhenhao Technology Consulting Partnership (Limited Partnership) | Corporate Entity | 348.00 | 1.38 |
| 5 | Shanghai Bingqing Private Fund Management Co., Ltd. - Bingqing Selection No. 1 Private Securities Investment Fund | Private Securities Investment Fund | 277.05 | 1.09 |
| 6 | Shanghai Bingqing Private Fund Management Co., Ltd. - Shanghai Bingqing Long-Short Quantitative No. 3 Private Securities Investment Fund | Private Securities Investment Fund | 225.16 | 0.89 |
| 7 | Guotai CESEC Livestock Breeding Exchange Traded Open End Index Securities Investment Fund | Fund | 211.08 | 0.83 |
5. Concept Sectors
- Energy Conservation & Environmental Protection
- Artificial Intelligence
- Medical Aesthetics Concept
- CXO Concept
- Sweetener Substitute Concept
- Helicobacter Pylori
- Fertilizer Concept
- Synthetic Biology
- Pet Economy
Remarks
- Data update date: 2025-09-30
- Data source: Public Market Information